Pharmacokinetics and pharmacodynamics of ruxolitinib: a review
TYJ Appeldoorn, THO Munnink, LM Morsink… - Clinical …, 2023 - Springer
Abstract Background and Objective Ruxolitinib is a tyrosine kinase inhibitor targeting the
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways …
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways …
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity
K Alim, A Bruyère, A Lescoat, E Jouan… - Expert opinion on …, 2021 - Taylor & Francis
ABSTRACT Introduction: Janus kinase inhibitors (JAKinibs) constitute an emerging and
promising pharmacological class of anti-inflammatory or anti-cancer drugs, used notably for …
promising pharmacological class of anti-inflammatory or anti-cancer drugs, used notably for …
The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine
Abstract P-glycoprotein (P-gp) is overexpressed in cancer cells in order to pump out
chemotherapeutic drugs, and is one of the major mechanisms responsible for multidrug …
chemotherapeutic drugs, and is one of the major mechanisms responsible for multidrug …
Regulation of ABC drug efflux transporters in human T-cells exposed to an HIV pseudotype
SK Whyte-Allman, R Kaul, R Bendayan - Frontiers in Pharmacology, 2021 - frontiersin.org
ATP-binding cassette (ABC) drug efflux transporters could contribute to low intracellular
concentrations of antiretroviral drugs in HIV-1 cell reservoirs and sanctuary sites …
concentrations of antiretroviral drugs in HIV-1 cell reservoirs and sanctuary sites …
Drug efflux transporters and metabolic enzymes in human circulating and testicular T-cell subsets: relevance to HIV pharmacotherapy
Objectives: ATP-binding cassette (ABC) drug efflux transporters and drug metabolic
enzymes could reduce antiretroviral concentrations in HIV target cells. The testis has been …
enzymes could reduce antiretroviral concentrations in HIV target cells. The testis has been …
Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
T Drabison, M Boeckman, Y Yang… - Cancer research …, 2024 - aacrjournals.org
Although the primary elimination pathway for most tyrosine kinase inhibitors (TKI) involves
CYP3A4-mediated metabolism, the mechanism by which these agents are brought into …
CYP3A4-mediated metabolism, the mechanism by which these agents are brought into …
COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein
J Lee, J Kim, J Kang, HJ Lee - Journal of Pharmaceutical Investigation, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2, has resulted in acute respiratory distress, fatal systemic …
respiratory syndrome coronavirus 2, has resulted in acute respiratory distress, fatal systemic …
Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters
Interactions of the Janus kinase (JAK) inhibitor ruxolitinib with solute carriers (SLCs) remain
incompletely characterised. The present study was therefore designed to investigate this …
incompletely characterised. The present study was therefore designed to investigate this …
ABCG2 is overexpressed on red blood cells in Ph-negative myeloproliferative neoplasms and potentiates Ruxolitinib-induced apoptosis
Myeloproliferative neoplasms (MPNs) are a group of disorders characterized by clonal
expansion of abnormal hematopoietic stem cells leading to hyperproliferation of one or more …
expansion of abnormal hematopoietic stem cells leading to hyperproliferation of one or more …
Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors
CP Wu, SC Hsu - Protein Kinase Inhibitors as Sensitizing Agents for …, 2019 - Elsevier
The overexpression of ATP-binding cassette (ABC) drug transporters contributes
significantly to the development of multidrug resistance (MDR) phenotype in cancer cells …
significantly to the development of multidrug resistance (MDR) phenotype in cancer cells …